Stockreport

Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF FDA approves asthma indication for Dupixent® (dupilumab) Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Only biolo [Read more]